Medical Excellence to fund cell, gene therapy, AI and regenerative medicine with $145M debut fund
Fund is led by John Prufeta and three Domain Associates alums
A new VC fund led by John Prufeta, Brian Halak, Eric Heil and Kim Kamdar will invest $145 million to support early-stage ventures in cell and gene therapies, AI/ML-powered drug discovery, synthetic biology, and regenerative medicine. The fund hopes to leverage a network of 1,200 physician-scientists, with which it is affiliated.
In announcing the final close of its debut fund Tuesday, Medical Excellence Capital (MEC) named seven investments it has made over the past year, including neuron replacement therapy company Aspen Neuroscience Inc. and first-in-class CD161 inhibitor company Immunitas Therapeutics Inc...